BACKGROUND: Experimental evidence has revealed that phosphodiesterase five inhibitors (PDE5is) increase epithelial barrier function and suppress intestinal carcinogenesis. Few epidemiological studies have investigated the role of PDE5i in increasing the risk of colorectal cancer (CRC); however, these studies have proffered varying conclusions. We therefore aimed to perform a comprehensive review and meta-analysis to investigate whether PDE5i use is associated with the incidence of CRC. METHODS: Databases, namely, PubMed, Scopus, Embase, and Web of Science, were used for literature search. Observational studies (published until January 31, 2021) that assessed the association of PDE5i use with CRC incidence were considered. Pooled relative risk (RR) estimates and corresponding 95% confidence intervals (CIs) were calculated using the DerSimonian-Laird random-effects model. RESULTS: We identified four retrospective studies that involved 965,044 participants and 3,518 CRC cases detected during a mean follow-up of 12.7 years. Pooled results indicated a significantly reduced CRC risk among all PDE5i users (RR, 0.85; 95% CI, 0.76-0.95; P = 0.004, I2 = 63%). Moreover, continuous use of PDE5i was associated with a significantly reduced risk of CRC (RR, 0.63; 95% CI, 0.59-0.68; P < 0.001, I2 = 0.0%). However, the type of PDE5i exhibited no association with the risk of CRC (RR, 1.00; 95% CI, 0.98-1.02; I2 = 84.7%). CONCLUSION: Our findings suggest that continuous use of PDE5i was associated with a significantly reduced risk of CRC development. Future studies with a longitudinal design and adequate control of confounding factors are required to clarify whether a longer duration of PDE5i use alters the risk of CRC.

Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic

Health Research Institute University of Canberra Canberra Australian Capital Territory Australia

University College of Pharmaceutical Sciences Kakatiya University Warangal India

Zobrazit více v PubMed

Peak TC, Richman A, Gur S, Yafi FA, Hellstrom WJG (2016) The role of PDE5 inhibitors and the NO/cGMP pathway in cancer. Sex Med Rev 4(1):74–84. https://doi.org/10.1016/j.sxmr.2015.10.004 PubMed DOI

Bian K, Murad F. sGC-cGMP signaling: target for anticancer therapy. Adv Fetal Neonatal Physiol 2014;5–13

Aoun F, Slaoui A, Walid AHO et al (2018) Association between phosphodiesterase type 5 inhibitors and prostate cancer: a systematic review. Prog Urol 28(12):560–566. https://doi.org/10.1016/j.purol.2018.07.004 PubMed DOI

Wu Y, Qu X, Wang Y et al (2019) Effect of phosphodiesterase type 5 inhibitors on prostate cancer risk and biochemical recurrence after prostate cancer treatment: A systematic review and meta-analysis. Andrologia 51(2):e13198. https://doi.org/10.1111/and.13198 PubMed DOI

Loeb S, Ventimiglia E, Salonia A, Folkvaljon Y, Stattin P (2017) Meta-analysis of the association between phosphodiesterase inhibitors (PDE5Is) and risk of melanoma. J Natl Cancer Inst 109(8). https://doi.org/10.1093/jnci/djx086

Loeb S, Folkvaljon Y, Lambe M et al (2015) Use of Phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma. JAMA 313(24):2449–2455. https://doi.org/10.1001/jama.2015.6604 PubMed DOI

Lin S, Wang J, Wang L et al (2017) Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res 7(1):41–52 PubMed PMC

Zhu B, Vemavarapu L, Thompson WJ, Strada SJ (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94(2):336–350. https://doi.org/10.1002/jcb.20286 PubMed DOI

Mei X-L, Yang Y, Zhang Y-J et al (2015) Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. Am J Cancer Res 5(11):3311–3324 PubMed PMC

Islam BN, Sharman SK, Hou Y et al (2017) Sildenafil suppresses inflammation-driven colorectal cancer in mice. Cancer Prev Res (Phila) 10(7):377–388. https://doi.org/10.1158/1940-6207.Capr-17-0015 DOI

Sutton SS, Magagnoli J, Cummings TH, Hardin JW (2020) The association between phosphodiesterase-5 inhibitors and colorectal cancer in a national cohort of patients. Clin Transl Gastroenterol 11(6):e00173. https://doi.org/10.14309/ctg.0000000000000173 PubMed DOI PMC

Cea Soriano L, García Rodríguez LA (2020) No association between use of phosphodiesterase 5 inhibitors and colorectal cancer in men with erectile dysfunction. Pharmacoepidemiol Drug Saf 29(5):605–608. https://doi.org/10.1002/pds.5000 PubMed DOI

Cronin KA, Lake AJ, Scott S et al (2018) Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 124(13):2785–2800 DOI

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535 PubMed DOI PMC

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–605 DOI

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statistics Med 21:1539–1558 DOI

Huang W, Sundquist J, Sundquist K, Ji J (2019 Sep) Use of phosphodiesterase 5 inhibitors is associated with lower risk of colorectal cancer in men with benign colorectal neoplasms. Gastroenterology 157(3):672-681.e4. https://doi.org/10.1053/j.gastro.2019.05.012 PubMed DOI

Matthews A, Langan SM, Douglas IJ, Smeeth L, Bhaskaran K (2016) Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med 13(6):e1002037. https://doi.org/10.1371/journal.pmed.1002037 PubMed DOI PMC

Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA (2010) Colon tumor cell growth–inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res 3(10):1303–1313 DOI

Mei XL, Yang Y, Zhang YJ, Li Y, Zhao JM, Qiu JG, Zhang WJ, Jiang QW, Xue YQ, Zheng DW, Chen Y (2015) Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. Am J Cancer Res 5(11):3311 PubMed PMC

Cruz-Burgos M, Losada-Garcia A, Cruz-Hernández CD, Cortés-Ramírez SA, Camacho-Arroyo I, Gonzalez-Covarrubias V, Morales-Pacheco M, Trujillo-Bornios SI, Rodríguez-Dorantes M (2021) New approaches in oncology for repositioning drugs: the case of PDE5 inhibitor sildenafil. Front Oncol 11:208 DOI